A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Running, not enrolling · Phase 1

Conditions studied: Advanced Solid Tumor, Advanced Solid Malignancies

In brief

This is a Phase I, multicenter, open-label, 3+3 dose escalation study to determine the safety and preliminary efficacy of PRJ1-3024 in subjects with relapsed/refractory solid tumors.

Key facts

Study ID

NCT05159700

Run by

Zhuhai Yufan Biotechnologies Co., Ltd

People needed

39

Starts

2022-03-31

Expected to finish

2026-06-29

Last updated by the study team

2025-12-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Sarah Cannon Research Institute at HealthONE — Denver, Colorado, United States
• Sarah Cannon Research Institute at Florida Cancer Specialists — Orlando, Florida, United States
• Christ Hospital — Cincinnati, Ohio, United States
• NEXT Oncology — Austin, Texas, United States
• Mays Cancer Center — San Antonio, Texas, United States
• NEXT Oncology — Fairfax, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.